Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hirotoshi Watanabe

Showing results (41-50 of 103) with videos related to

Pageof 11
Sort By:
Cardiovascular Intervention and Therapeutics|September 21, 2016
Short versus prolonged dual antiplatelet therapy duration after bare-metal stent implantation: 2-month landmark analysis from the CREDO-Kyoto registry cohort-2Masahiro Natsuaki, Takeshi Morimoto, Yutaka Furukawa, et al.
Circulation. Cardiovascular Interventions|May 14, 2025
Aspirin-Free Strategy for PCI in Patients With High Bleeding Risk With or Without Acute Coronary Syndrome: A Subgroup Analysis From the STOPDAPT-3 TrialTetsuya Ishikawa, Masahiro Natsuaki, Hirotoshi Watanabe, et al.
JACC. Cardiovascular Interventions|June 5, 2025
Aspirin vs Clopidogrel 1 Month After Acute Coronary Syndrome With High-Bleeding Risk or ST-Segment ElevationYuki Obayashi, Masahiro Natsuaki, Hirotoshi Watanabe, et al.
JACC. Cardiovascular Interventions|May 15, 2024
An Aspirin-Free Strategy for Immediate Treatment Following Complex Percutaneous Coronary InterventionKo Yamamoto, Masahiro Natsuaki, Hirotoshi Watanabe, et al.
Circulation Reports|June 11, 2025
An Aspirin-Free Strategy for Patients Undergoing Staged Percutaneous Coronary Intervention　- A Subgroup Analysis of the STOPDAPT-3 TrialKo Yamamoto, Masahiro Natsuaki, Hirotoshi Watanabe, et al.
Journal of the American Heart Association|July 26, 2024
Aspirin-Free Strategy for Percutaneous Coronary Intervention in Patients With Oral Anticoagulation: Prespecified Subgroup Analysis From the STOPDAPT-3 TrialMasahiro Natsuaki, Hirotoshi Watanabe, Takeshi Morimoto, et al.
Plos One|March 27, 2020
One-year clinical outcomes of patients with versus without acute coronary syndrome with 3-month duration of dual antiplatelet therapy after everolimus-eluting stent implantationMasahiro Natsuaki, Takeshi Morimoto, Erika Yamamoto, et al.
Eurointervention : Journal of Europcr in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology|July 3, 2023
Biodegradable or durable polymer drug-eluting stents in patients with coronary artery disease: ten-year outcomes of the randomised NEXT TrialMasahiro Natsuaki, Hirotoshi Watanabe, Takeshi Morimoto, et al.
Circulation Journal : Official Journal of the Japanese Circulation Society|September 14, 2022
Low-Density Lipoprotein Cholesterol Levels on Statins and Cardiovascular Event Risk in Stable Coronary Artery Disease　- An Observation From the REAL-CAD StudyToshiaki Toyota, Takeshi Morimoto, Satoshi Iimuro, et al.
JACC. Asia|November 7, 2022
Stent-Related Adverse Events as Related to Dual Antiplatelet Therapy in First- vs Second-Generation Drug-Eluting StentsYusuke Yoshikawa, Hiroki Shiomi, Takeshi Morimoto, et al.
Pageof 11

Showing results (41-50 of 103) with videos related to

Sort By:
Pageof 11
Cardiovascular Intervention and Therapeutics|September 21, 2016
Short versus prolonged dual antiplatelet therapy duration after bare-metal stent implantation: 2-month landmark analysis from the CREDO-Kyoto registry cohort-2Masahiro Natsuaki, Takeshi Morimoto, Yutaka Furukawa, et al.
Circulation. Cardiovascular Interventions|May 14, 2025
Aspirin-Free Strategy for PCI in Patients With High Bleeding Risk With or Without Acute Coronary Syndrome: A Subgroup Analysis From the STOPDAPT-3 TrialTetsuya Ishikawa, Masahiro Natsuaki, Hirotoshi Watanabe, et al.
JACC. Cardiovascular Interventions|June 5, 2025
Aspirin vs Clopidogrel 1 Month After Acute Coronary Syndrome With High-Bleeding Risk or ST-Segment ElevationYuki Obayashi, Masahiro Natsuaki, Hirotoshi Watanabe, et al.
JACC. Cardiovascular Interventions|May 15, 2024
An Aspirin-Free Strategy for Immediate Treatment Following Complex Percutaneous Coronary InterventionKo Yamamoto, Masahiro Natsuaki, Hirotoshi Watanabe, et al.
Circulation Reports|June 11, 2025
An Aspirin-Free Strategy for Patients Undergoing Staged Percutaneous Coronary Intervention　- A Subgroup Analysis of the STOPDAPT-3 TrialKo Yamamoto, Masahiro Natsuaki, Hirotoshi Watanabe, et al.
Journal of the American Heart Association|July 26, 2024
Aspirin-Free Strategy for Percutaneous Coronary Intervention in Patients With Oral Anticoagulation: Prespecified Subgroup Analysis From the STOPDAPT-3 TrialMasahiro Natsuaki, Hirotoshi Watanabe, Takeshi Morimoto, et al.
Plos One|March 27, 2020
One-year clinical outcomes of patients with versus without acute coronary syndrome with 3-month duration of dual antiplatelet therapy after everolimus-eluting stent implantationMasahiro Natsuaki, Takeshi Morimoto, Erika Yamamoto, et al.
Eurointervention : Journal of Europcr in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology|July 3, 2023
Biodegradable or durable polymer drug-eluting stents in patients with coronary artery disease: ten-year outcomes of the randomised NEXT TrialMasahiro Natsuaki, Hirotoshi Watanabe, Takeshi Morimoto, et al.
Circulation Journal : Official Journal of the Japanese Circulation Society|September 14, 2022
Low-Density Lipoprotein Cholesterol Levels on Statins and Cardiovascular Event Risk in Stable Coronary Artery Disease　- An Observation From the REAL-CAD StudyToshiaki Toyota, Takeshi Morimoto, Satoshi Iimuro, et al.
JACC. Asia|November 7, 2022
Stent-Related Adverse Events as Related to Dual Antiplatelet Therapy in First- vs Second-Generation Drug-Eluting StentsYusuke Yoshikawa, Hiroki Shiomi, Takeshi Morimoto, et al.
Pageof 11